AU2006226192A1 - Improvements in or relating to treatment and prevention of viral infections - Google Patents

Improvements in or relating to treatment and prevention of viral infections Download PDF

Info

Publication number
AU2006226192A1
AU2006226192A1 AU2006226192A AU2006226192A AU2006226192A1 AU 2006226192 A1 AU2006226192 A1 AU 2006226192A1 AU 2006226192 A AU2006226192 A AU 2006226192A AU 2006226192 A AU2006226192 A AU 2006226192A AU 2006226192 A1 AU2006226192 A1 AU 2006226192A1
Authority
AU
Australia
Prior art keywords
hcv
antibody
immunoglobulin
group
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2006226192A
Other languages
English (en)
Inventor
Jonathan Ball
Arvind Patel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical Research Council
Original Assignee
Medical Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0505697A external-priority patent/GB0505697D0/en
Application filed by Medical Research Council filed Critical Medical Research Council
Publication of AU2006226192A1 publication Critical patent/AU2006226192A1/en
Priority to AU2012254920A priority Critical patent/AU2012254920A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/116—Togaviridae (F); Matonaviridae (F); Flaviviridae (F)
    • C07K16/118—Hepatitis C virus; GB virus C [GBV-C]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2006226192A 2005-03-19 2006-03-20 Improvements in or relating to treatment and prevention of viral infections Abandoned AU2006226192A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2012254920A AU2012254920A1 (en) 2005-03-19 2012-11-16 Improvements in or relating to treatment and prevention of viral infections

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB0505697.3 2005-03-19
GB0505697A GB0505697D0 (en) 2005-03-19 2005-03-19 Improvements in or relating to treatment and prevention of viral infection
US31512305A 2005-12-23 2005-12-23
US11/315,123 2005-12-23
GB0526421A GB0526421D0 (en) 2005-03-19 2005-12-23 Improvements in or relating to treatment and prevention of viral infections
GB0526421.3 2005-12-23
PCT/GB2006/000987 WO2006100449A1 (en) 2005-03-19 2006-03-20 Improvements in or relating to treatment and prevention of viral infections

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2012254920A Division AU2012254920A1 (en) 2005-03-19 2012-11-16 Improvements in or relating to treatment and prevention of viral infections

Publications (1)

Publication Number Publication Date
AU2006226192A1 true AU2006226192A1 (en) 2006-09-28

Family

ID=36754660

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006226192A Abandoned AU2006226192A1 (en) 2005-03-19 2006-03-20 Improvements in or relating to treatment and prevention of viral infections

Country Status (6)

Country Link
US (2) US20090110685A1 (https=)
EP (2) EP2481424A1 (https=)
JP (1) JP2008532559A (https=)
AU (1) AU2006226192A1 (https=)
CA (1) CA2601400A1 (https=)
WO (1) WO2006100449A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2694397A1 (en) * 2007-07-25 2009-01-29 Japan As Represented By Director-General Of National Institute Of Infect Ious Diseases Antibody having inhibitory activity on infection with hepatitis c virus (hcv) and use thereof
JP5763344B2 (ja) * 2007-12-17 2015-08-12 メディカル リサーチ カウンシル テクノロジー Ｃ型肝炎ウイルス抗体
US20100104555A1 (en) * 2008-10-24 2010-04-29 The Scripps Research Institute HCV neutralizing epitopes
MX2011006516A (es) 2008-12-17 2011-08-04 Genentech Inc Terapia de combinacion de virus de hepatitis c.
EP2473531A4 (en) * 2009-09-03 2013-05-01 Merck Sharp & Dohme Anti-gitr antibodies
WO2011052735A1 (ja) * 2009-10-30 2011-05-05 東レ株式会社 C型肝炎ウイルス（hcv）に対して感染阻害活性を有する抗体及びその用途
ITFI20120122A1 (it) 2012-06-15 2013-12-16 Kedrion S P A 50 Anticorpi monoclonali capaci di legare la proteina virale e2 loro preparazione ed uso.
WO2014116749A1 (en) 2013-01-23 2014-07-31 Genentech, Inc. Anti-hcv antibodies and methods of using thereof
RU2539770C1 (ru) 2013-12-27 2015-01-27 Татьяна Николаевна Власик Способ нейтрализации вируса гепатита с, полностью человеческое моноклональное антитело против вируса гепатита с (варианты), композиция полностью человеческих моноклональных антител против вируса гепатита с и гибридная мышь/человек клеточная линия - продуцент полностью человеческих моноклональных антител против вируса гепатита с (варианты)
WO2015141826A1 (ja) * 2014-03-20 2015-09-24 国立感染症研究所長が代表する日本国 Ｃ型肝炎ウイルスに対する感染阻害活性を有する抗体
GB201415714D0 (en) 2014-09-05 2014-10-22 Medical Res Council Antibodies and antigen binding fragments thereof
EP3189077A2 (en) * 2014-09-05 2017-07-12 Aimm Therapeutics B.V. Hepatitis c virus specific antibody
WO2018156180A1 (en) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
MY205459A (en) * 2018-12-06 2024-10-22 Cytomx Therapeutics Inc Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US4631211A (en) 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
SU1618761A1 (ru) 1987-04-29 1991-01-07 Институт Белка Ан Ссср Способ получени пептидов и белков в бесклеточной системе трансл ции
ATE243754T1 (de) 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
AU649217B2 (en) 1988-11-18 1994-05-19 Regents Of The University Of California, The Method for site-specifically incorporating unnatural amino acids into proteins
SU1705302A1 (ru) 1988-12-22 1992-01-15 Институт Белка Ан Ссср Способ препаративной экспрессии генов в бесклеточной системе сопр женной транскрипции/трансл ции
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
DK0593757T3 (da) 1989-07-31 1997-07-07 Inst Of Protein Research Russi Fremgangsmåde til opnåelse af polypeptider i et cellefrit system
DK0494955T3 (da) 1989-10-05 1998-10-26 Optein Inc Cellefri syntese og isolering af hidtil ukendte gener og polypeptider
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP0438310A1 (en) 1990-01-19 1991-07-24 Merck & Co. Inc. Method for producing recombinant immunoglobuline
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5503978A (en) 1990-06-11 1996-04-02 University Research Corporation Method for identification of high affinity DNA ligands of HIV-1 reverse transcriptase
US5654151A (en) 1990-06-11 1997-08-05 Nexstar Pharmaceuticals, Inc. High affinity HIV Nucleocapsid nucleic acid ligands
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5567588A (en) 1990-06-11 1996-10-22 University Research Corporation Systematic evolution of ligands by exponential enrichment: Solution SELEX
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
EP0585287B1 (en) 1990-07-10 1999-10-13 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
AU8498091A (en) 1990-08-02 1992-03-02 Regents Of The University Of Colorado, The Systematic polypeptide evolution by reverse translation
WO1992005258A1 (en) 1990-09-20 1992-04-02 La Trobe University Gene encoding barley enzyme
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
DE69132531T2 (de) 1990-12-06 2001-09-13 Affymetrix, Inc. (N.D.Ges.D.Staates Delaware) Verbindungen und ihre Verwendung in einer binären Synthesestrategie
EP0563296B1 (en) 1990-12-20 1999-03-17 Ixsys, Inc. Optimization of binding proteins
CA2104698A1 (en) 1991-02-21 1992-08-22 John J. Toole Aptamers specific for biomolecules and methods of making
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
AU732820B2 (en) 1995-06-02 2001-05-03 Nexstar Pharmaceuticals, Inc. High-affinity oligonucleotide ligands to growth factors
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
JP2001524926A (ja) 1991-09-18 2001-12-04 アフィマックス テクノロジーズ ナームロゼ フェンノートシャップ オリゴマーの雑多ライブラリーの集合体を合成する方法
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
EP1291360A1 (en) 1991-12-13 2003-03-12 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
AU8124694A (en) 1993-10-29 1995-05-22 Affymax Technologies N.V. In vitro peptide and antibody display libraries
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
CU22615A1 (es) 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
GB9416721D0 (en) 1994-08-18 1994-10-12 Short Brothers Plc A bias yarn assembly forming device
AU725609C (en) 1995-08-18 2002-01-03 Morphosys Ag Protein/(poly)peptide libraries
GB9603507D0 (en) * 1996-02-20 1996-04-17 Isis Innovation Antibody variants
US5766686A (en) 1996-03-01 1998-06-16 North American Refractories Co. Spray insulating coating for refractory articles
WO1998052976A1 (en) 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins
US5887293A (en) 1998-01-28 1999-03-30 Hennessy; Arnold Simplified dump bucket toilet
WO2000034317A2 (en) 1998-12-08 2000-06-15 Biovation Limited Method for reducing immunogenicity of proteins
US7201904B2 (en) * 2002-05-16 2007-04-10 The General Hospital Corporation Epitopes of hepatitis C virus
CN1822856B (zh) * 2003-07-11 2010-04-28 英特塞尔股份公司 Hcv疫苗
US20050266425A1 (en) 2003-12-31 2005-12-01 Vaccinex, Inc. Methods for producing and identifying multispecific antibodies
MX2011006516A (es) * 2008-12-17 2011-08-04 Genentech Inc Terapia de combinacion de virus de hepatitis c.

Also Published As

Publication number Publication date
WO2006100449A1 (en) 2006-09-28
CA2601400A1 (en) 2006-09-28
EP2481424A1 (en) 2012-08-01
JP2008532559A (ja) 2008-08-21
US20090110685A1 (en) 2009-04-30
US20140322204A1 (en) 2014-10-30
EP1863531A1 (en) 2007-12-12

Similar Documents

Publication Publication Date Title
US20090110685A1 (en) Treatment and prevention of viral infections
CN108137675B (zh) 中和乙型肝炎病毒的抗体和其用途
KR102558839B1 (ko) 다가 b형 간염 바이러스 항원 결합 분자 및 그의 용도
Tarr et al. An alpaca nanobody inhibits hepatitis C virus entry and cell‐to‐cell transmission
JP5642972B2 (ja) Ｃ型肝炎ウイルス（ｈｃｖ）に対するヒト抗体およびその使用
US8840895B2 (en) Human antibodies specifically binding to the hepatitis B virus surface antigen
JP2002521391A (ja) 抗ｃ型肝炎ウイルス抗体およびその使用
CN114716541A (zh) 抗冠状病毒的全人广谱中和抗体76e1及其应用
KR101450955B1 (ko) Ｈｃｖ 감염의 치료적 처리 및 예방을 위한 의약으로서 항 ｈｃｖ 모노클로날 항체
US20070287667A1 (en) Anti-hepatitis a virus antibodies
JP2005510201A (ja) Ｈｉｖ−１に対する中和ヒトモノクローナル抗体、それらの産生および使用
JP2000509966A (ja) Ｃ型肝炎ウイルス（ｈｃｖ）ｅ２抗原に特異的なヒトモノクローナル抗体
US20140046034A1 (en) Antibody having activity of inhibiting hepatitus c virus (hcv) infection and use thereof
US6924362B2 (en) Monoclonal antibodies specific for the E2 glycoprotein of hepatitic C virus and their use in the diagnosis, treatment, and prevention of hepatitis C
JP2004504066A (ja) Ｃ型肝炎ウイルスｅ２糖蛋白質に対するヒトモノクローナル抗体
JP2007014267A (ja) Ｂ型肝炎ウイルスのＨＢｓ抗原に対するモノクローナル抗体、それに関連する遺伝子およびペプチド、並びにＢ型肝炎ウイルスの検定方法、Ｂ型肝炎の診断方法、治療方法
AU2012254920A1 (en) Improvements in or relating to treatment and prevention of viral infections
HK1173979A (en) Improvements in or relating to treatment and prevention of hepatitis c viral infections
JP2013230152A (ja) ウイルス感染の治療及び予防又は治療及び予防の改善
WO2002059340A1 (en) Immunopolypeptides to hepatitis c virus
HK40074417A (en) Antibodies that neutralize hepatitis b virus and uses thereof
HK40074418A (en) Antibodies that neutralize hepatitis b virus and uses thereof
HK40074418B (zh) 中和乙型肝炎病毒的抗体和其用途
CN111153989A (zh) Echo30单克隆抗体的制备及其用途
HK1158232A1 (en) Therapeutic use of specific ligand in msrv associated diseases

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted